1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [chandanalakshmi999@gmail.com].
   


6. For how long will this data be available start date provided 01-01-2026 and end date provided 31-12-2026?
   Response (Others) -  one year post to publication


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - nil

   Respiratory diseases are the greatest cause of pediatric medical visits,  nasal obstruction is most common.¹Adenoid hypertrophy(AH) is an obstructive condition due to increased size of adenoids². Adenoids being a part of immune system and act as the first line of defence mechanism of aerodigestive tract³, they can get inflamed and enlarged by allergy of upper respiratory tract  recurrent attacks of  rhinitis , sinusitis or chronic tonsilitis⁴.^.

   Adenoid hypertrophy occupies the most among all diseases of the upper respiratory tract in paediatric, accounting for about 34.5% according to NCBI a systematic review and Metaanalysis⁵. 0-75% adenoids enlargement is diagnosed at 3-10 years. The symptoms of adenoid hypertrophy tend to occur more among young children, because of the increased frequency of upper respiratory tract infections and the small volume of the nasopharynx.  Even though  this condition is generally self-resolving due to age-related adenoid atrophy,  AH can lead to a series of serious complications including sleep-disordered breathing and sleep apnea which in children can lead to growth failure, and neurocognitive abnormalities such as low intelligence quotient, learning and behavioral problems, poor attention span,ear infections, temporary hearing loss and Pulmonary hypertension⁶.

   The treatment options available for  adenoid hypertrophy are antibiotics, antihistamines  , nasal steroidsand surgical management called adenoidectomy may result in postoperative complications such as immediate and late bleeding (0.7%)⁷ ,vomiting  ,difficulties in swallowing and pain .recurrence of adenoid tissue is 20% The  risk of adenoid re-growth is slightly more common in patients who undergo adenoidectomy at a young age⁸.The complications arising from the medical and surgical management makes us to find out the alternative line of management with no added adverse effect .

   In Ayurveda, adenoid enlargement can be well correlated with Kanthashaluka⁹owing to the marked similarities of the clinical presentations of hypertrophied adenoids like margarodha,kolavath granti¹⁰.As it is  an urdhwajatrugatavikara and nasya is widely adopted and effective treatment modalityfor the management¹¹, in the present study pratimarshanasya is taken as choice of intervention . As the disease is kaphapradhana the drug of choice should have,katu rasa,ushnateekshna guna¹²hence apamargataila is selected for pratimarshanasya and kumarabharana tablet internally.

   As apamarga is having katutikta rasa ushnaveerya,shodana and ropana property, it is  taken as drug of choice and Kumarabharana Rasa is Anubhuta Yoga (formulation) which is very effective in management of chronic respiratory diseases especially in children as it is observed during the clinical practice¹³ .Hence in the present study an attempt is made to evaluate the combined effect of prathimarshanasya with apamargaksharatailaand kumarabharana tablet internally in hypertrophied adenoids